

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT

DISEASE Unknown primary carcinoma (NOS)

NAME E

DATE OF BIRTH 01/01/1970

SEX Female

MEDICAL RECORD # Not given

PHYSICIAN

ORDERING PHYSICIAN F. J. Arias, M.D.

MEDICAL FACILITY Arias Stella

ADDITIONAL RECIPIENT None

MEDICAL FACILITY ID 317319

PATHOLOGIST Not Provided

SPECIMEN

SPECIMEN SITE Kidney

SPECIMEN ID H21 05309-1A

SPECIMEN TYPE Block

DATE OF COLLECTION 06 July 2021

SPECIMEN RECEIVED 29 July 2021

Biomarker Findings

Microsatellite status - MS-Stable

Tumor Mutational Burden - 8 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

PBRM1 D18fs*27

SETD2 Q7*

VHL N141fs*3

☐ Therapies with Clinical Benefit

☐ Clinical Trials

☐ Therapies with Resistance

BIOMARKER FINDINGS

Microsatellite status - MS-Stable

Tumor Mutational Burden - 8 Muts/Mb

THERAPY AND CLINICAL TRIAL IMPLICATIONS

No therapies or clinical trials. see Biomarker Findings section

No therapies or clinical trials. see Biomarker Findings section

No therapies or clinical trials are associated with the Genomic Findings for this sample.

If you have questions or comments about this result, please contact your Foundation Medicine customer support representative.

Phone: 1-888-988-3639

Online: foundationmedicine.com

Email: client.services@foundationmedicine.com

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING IN SELECT CANCER SUSCEPTIBILITY GENES

Findings below have been previously reported as pathogenic germline in the ClinVar genomic database and were detected at an allele frequency of >10%. See appendix for details.

VHL - N141fs*3 p. 5

This report does not indicate whether variants listed above are germline or somatic in this patient. In the appropriate clinical context, follow-up germline testing would be needed to determine whether a finding is germline or somatic.

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

PBRM1 - D18fs*27 p. 4 **VHL - N141fs*3** p. 5
SETD2 - Q7* p. 4

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

ORDERED TEST # ORD-1156176-01

BIOMARKER FINDINGS

BIOMARKER

Microsatellite status

RESULT

MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors¹⁻³, including approved therapies nivolumab and pembrolizumab⁴. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, $p=0.001$)⁵.

FREQUENCY & PROGNOSIS

MSI-high (MSI-H) has been observed at high frequency in endometrial cancers (14-33%)⁶⁻¹³, colorectal cancers (CRCs; 10-15%)^{3,14-17}, and gastric cancers (12-35%)¹⁸⁻²¹ and at lower frequencies in many other tumor types, including esophageal²², small bowel²³⁻²⁷, hepatobiliary²⁸⁻³⁴, prostate³⁵⁻³⁷, and urinary tract carcinomas³⁸⁻⁴⁰. In one study, MSI-H status was associated with a positive prognostic effect in patients with gastric cancer treated with surgery alone and a negative predictive effect in patients treated with chemotherapy⁴¹. Data regarding the role of MSI-H on prognosis and survival in endometrial cancer are conflicting^{6,9-10,12,42-44}. However, studies specifically analyzing early stage endometrial cancer have reported a correlation between MSI-H and decreased survival^{8,11,13,43}, thereby suggesting that MSI-H predicts for poor prognosis in this subset of endometrial tumors.

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor¹⁶. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2^{16,45-46}. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers^{15,47-48}. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins^{15-16,46,48}.

BIOMARKER

Tumor Mutational Burden

RESULT

8 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1⁴⁹⁻⁵¹, anti-PD-1 therapies⁴⁹⁻⁵², and combination nivolumab and ipilimumab⁵³⁻⁵⁸. In multiple pan-tumor studies, higher TMB has been reported to be associated with increased ORR and OS from treatment with immune checkpoint inhibitors^{49-52,59}. Higher TMB was found to be significantly associated with improved OS upon immune checkpoint inhibitor treatment for patients with 9 types of advanced tumors⁴⁹. Analyses across several solid tumor types reported that patients with higher TMB (defined as ≥ 16 -20 Muts/Mb) achieved greater clinical benefit from PD-1 or PD-L1-targeting monotherapy, compared with patients with higher TMB treated with chemotherapy⁶⁰ or those with lower TMB treated

with PD-1 or PD-L1-targeting agents⁵⁰. However, the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors found significant improvement in ORR for patients with TMB ≥ 10 Muts/Mb (based on this assay or others) compared to those with TMB < 10 Muts/Mb, in a large cohort that included multiple tumor types; similar findings were observed in the KEYNOTE 028 and 012 trials^{52,59}. Together, these studies suggest that patients with TMB ≥ 10 Muts/Mb may derive clinical benefit from PD-1 or PD-L1 inhibitors.

FREQUENCY & PROGNOSIS

Carcinomas that have been reported to harbor the highest frequencies of elevated TMB include colorectal (CRC) (8-25%)^{17,61}, endometrial (7-24%)⁶², intestinal type gastric (20%)⁶³, and non-small cell lung carcinoma (NSCLC; 8-13%)⁶⁴⁻⁶⁵. In patients with NSCLC, increased TMB is associated with higher tumor grade and poor prognosis⁶⁶, as well as with a decreased frequency of known driver mutations in EGFR, ALK, ROS1, or MET (1% of high-TMB samples each), but not BRAF (10.3%) or KRAS (9.4%)⁶⁴. Although some studies have reported a lack of association between smoking and increased TMB in NSCLC⁶⁶⁻⁶⁷, several other large studies did find a strong link⁶⁸⁻⁷¹. In CRC, elevated TMB is associated with a higher frequency of BRAF V600E driver mutations^{17,61}

and with microsatellite instability (MSI)⁶¹, which in turn has been reported to correlate with better prognosis^{14,72-78}. Although increased TMB is associated with increased tumor grade in endometrioid endometrial carcinoma^{62,79-81} and bladder cancer⁸², it is also linked with improved prognosis in patients with these tumor types⁶².

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma⁸³⁻⁸⁴ and cigarette smoke in lung cancer⁸⁵⁻⁸⁶, treatment with temozolomide-based chemotherapy in glioma⁸⁷⁻⁸⁸, mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes^{17,62,89-91}, and microsatellite instability (MSI)^{17,62,91}. This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD-1- or PD-L1-targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types^{50-51,59}.

ORDERED TEST # ORD-1156176-01

GENOMIC FINDINGS

GENE

PBRM1

ALTERATION

D18fs*27

TRANSCRIPT ID

NM_018313

CODING SEQUENCE EFFECT

52delG

VARIANT ALLELE FREQUENCY (% VAF)

27.2%

benefit from various immune checkpoint inhibitors in other solid tumor types, including non-small cell lung cancer, urothelial carcinoma, melanoma, or esophagogastric cancer, suggesting that the impact of PBRM1 loss of function may depend on tumor type⁹⁵⁻⁹⁸.

FREQUENCY & PROGNOSIS

Somatic mutations in PBRM1 are prevalent in clear cell renal cell carcinomas (ccRCC) (41%)⁹⁹, intrahepatic cholangiocarcinomas (9-13%)¹⁰⁰⁻¹⁰³, and bladder urothelial carcinomas (6-14%)¹⁰⁴⁻¹⁰⁶. PBRM1 mutations are detected in other tumor types, including in 37% (11/30) of papillary meningiomas and 4% (2/54) of thymic carcinomas¹⁰⁷⁻¹⁰⁸ and in skin (6%), large intestine (5%), stomach (5%), soft tissue (3%), and lung (2%) (COSMIC, 2021)¹⁰⁹. Preclinical studies have shown that loss of PBRM1 increases the proliferation of ccRCC cell lines⁹⁹. PBRM1 protein loss or mutation is correlated with late tumor stage, low differentiation grade, and/or poor patient prognosis in ccRCC¹¹⁰⁻¹¹², extrahepatic cholangiocarcinoma¹⁰², and pancreatic cancer¹¹³. However, one ccRCC study reported no

correlation between PBRM1 mutation and cancer-specific survival¹¹⁴. In ccRCC, PBRM1 alterations are generally observed to be mutually exclusive with BAP1 alterations^{99,115}; a retrospective analysis of 145 primary ccRCCs found a decreased median overall survival for patients with mutations in both BAP1 and PBRM1 compared with patients having either mutated gene alone¹¹⁶. A trend toward worse survival was also seen in patients with intrahepatic cholangiocarcinoma harboring mutations in chromatin modifiers (including BAP1, ARID1A, or PBRM1)¹⁰¹.

FINDING SUMMARY

PBRM1 (Polybromo-1), also known as BAF180, encodes a subunit of ATP-dependent chromatin-remodeling complexes and a required cofactor for ligand-dependent transactivation by nuclear hormone receptors¹¹⁷. Mutation, loss, or inactivation of PBRM1 has been reported in several cancers, suggesting PBRM1 is a tumor suppressor^{99,101,118}. Alterations such as seen here may disrupt PBRM1 function or expression¹¹⁹⁻¹²⁴.

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of significant clinical data from prospective studies, PBRM1 inactivation may predict benefit from PD-1-targeting immune checkpoint inhibitors, such as nivolumab, pembrolizumab, cemiplimab, or dostarlimab, for patients with clear cell renal cell carcinoma and prior anti-angiogenic therapy⁹²⁻⁹⁴. However, multiple retrospective analyses report that PBRM1 mutation status is not associated with clinical

GENE

SETD2

ALTERATION

Q7*

TRANSCRIPT ID

NM_014159

CODING SEQUENCE EFFECT

19C>T

VARIANT ALLELE FREQUENCY (% VAF)

35.3%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no targeted therapies available to address genomic alterations in SETD2.

FREQUENCY & PROGNOSIS

Somatic inactivating alterations of SETD2 are documented to occur at low frequency in a number of solid tumors, most commonly in renal carcinoma⁹⁹. SETD2 has been associated with favorable prognosis in gastric cancer¹²⁵. SETD2 has also been associated with poor prognosis in RCC and MDS¹²⁶, while data in other tumor types is limited (PubMed, Jun 2021).

FINDING SUMMARY

SETD2 encodes a histone lysine-36 methyltransferase¹²⁷ that preferentially interacts with the expanded N-terminal polyglutamine tracts present in mutant huntingtin, implicating it in the pathogenesis of Huntington disease¹²⁸. SETD2 mRNA expression has been observed to be consistently reduced in breast tumors relative to adjacent non-tumor tissue, suggesting a potential tumor suppressor role¹²⁹. SETD2 alterations such as observed here have been shown to be inactivating¹³⁰⁻¹³⁵.

ORDERED TEST # ORD-1156176-01

GENOMIC FINDINGS

GENE

VHL

ALTERATION

N141fs*3

TRANSCRIPT ID

NM_000551

CODING SEQUENCE EFFECT

420_421insC

VARIANT ALLELE FREQUENCY (% VAF)

24.2%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Various strategies are under clinical investigation to block pathways downstream of inactivated VHL, including HIF, VEGF, and mTOR. The multikinase inhibitor sunitinib, which has activity against VEGFRs and other targets, is approved to treat several tumor types and has shown strong efficacy in patients with VHL disease¹³⁶⁻¹⁴⁰. Several clinical trials found response rates up to 64% and disease control rates up to 90%¹⁴¹⁻¹⁴². However, multiple clinical studies of sunitinib in patients with renal cell carcinoma reported that mutation or inactivation of the VHL gene is not significantly associated with therapeutic response or survival¹⁴³⁻¹⁴⁵. Other agents that inhibit VEGFRs, including the multikinase inhibitors sorafenib, axitinib, pazopanib, regorafenib, cabozantinib, and vandetanib; the anti-VEGFR2

antibody ramucirumab; and the mTOR inhibitors everolimus and temsirolimus, are also approved in multiple tumor types. However, studies have similarly shown that VHL mutation or inactivation does not correlate with responses to these agents^{144,146-147}. Therefore, it is unclear whether these therapeutic strategies would be beneficial in this case. The HIF2a inhibitor belzutifan achieved an ORR of 36% in a clinical trial for VHL disease-associated clear cell renal cell carcinoma¹⁴⁸. Responses were also seen in other VHL mutation-associated tumor types, including CNS hemangioblastomas and pancreatic neuroendocrine tumors; however, it was not determined whether VHL inactivation was significantly associated with these responses¹⁴⁸.

FREQUENCY & PROGNOSIS

VHL mutations have been reported in 4.5% of all tumor samples analyzed in COSMIC, including 51% of renal clear cell carcinomas, 35% of hemangioblastomas, and 6.4% of pheochromocytomas (Feb 2021)¹⁰⁹. Studies exploring the prognostic value of VHL mutation in RCC have given mixed results¹⁴⁹. In colorectal cancer, increased pVHL expression has been observed at the invading tumor margin and correlated with worse disease-free survival¹⁵⁰. In contrast, VHL has been reported to be hypermethylated and downregulated in non-small cell lung cancer¹⁵¹, and VHL copy number loss was associated with poor survival in this tumor type¹⁵².

FINDING SUMMARY

VHL encodes the protein pVHL (von Hippel-Lindau tumor suppressor), which is frequently inactivated, either via mutation or hypermethylation, in clear cell renal cell carcinoma (ccRCC) and plays an important role in its pathogenesis¹⁵³. Inactivating mutations in VHL lead to dysregulation of critical downstream growth regulators, especially members of the HIF family and VEGF¹⁵⁴⁻¹⁵⁵. Alterations such as seen here may disrupt VHL function or expression¹⁵⁶⁻¹⁹⁴.

POTENTIAL GERMLINE IMPLICATIONS

One or more of the VHL variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with von Hippel-Lindau syndrome (ClinVar, Mar 2021)¹⁹⁵. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Inactivating germline mutations in VHL underlie von Hippel-Lindau syndrome, a rare but highly penetrant autosomal dominant syndrome occurring in 1/36,000 live births that predisposes to the development of several types of cancer, including clear cell renal cell carcinomas and pancreatic neuroendocrine tumors, as well as retinal and central nervous system hemangioblastomas¹⁹⁶⁻¹⁹⁸. In the appropriate clinical context, germline testing of VHL is recommended.

ORDERED TEST # ORD-1156176-01

APPENDIX
Variants of Unknown Significance

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

AXL
R190C

FLT1
R1045Q

GATA4
P80S

KMT2A (MLL)
A53V

MSH2
R929Q

TSC1
K587R

ORDERED TEST # ORD-1156176-01

APPENDIX
Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	ACVR1B	AKT1	AKT2	AKT3	ALK	ALOX12B	AMER1 (FAM123B)	APC
AR	ARAF	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX	AURKA
AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2	BCL6
BCOR	BCORL1	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1	BTG2
BTB	C11orf30 (EMSY)	C17orf39 (GID4)	CALR	CARD11	CASP8	CBFB	CBL	CCND1
CCND2	CCND3	CCNE1	CD22	CD274 (PD-L1)	CD70	CD79A	CD79B	CDC73
CDH1	CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2B
CDKN2C	CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	CSF3R
CTCF	CTNNA1	CTNNB1	CUL3	CUL4A	CXCR4	CYP17A1	DAXX	DDR1
DDR2	DIS3	DNMT3A	DOT1L	EED	EGFR	EP300	EPHA3	EPHB1
EPHB4	ERBB2	ERBB3	ERBB4	ERCC4	ERG	ERRF1	ESR1	EZH2
FAM46C	FANCA	FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	FGF12
FGF14	FGF19	FGF23	FGF3	FGF4	FGF6	FGFR1	FGFR2	FGFR3
FGFR4	FH	FLCN	FLT1	FLT3	FOXO2	FUBP1	GABRA6	GATA3
GATA4	GATA6	GNA11	GNA13	GNAQ	GNAS	GRM3	GSK3B	H3F3A
HDAC1	HGF	HNF1A	HRAS	HSD3B1	ID3	IDH1	IDH2	IGF1R
IKBKE	IKZF1	INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2	JAK3
JUN	KDMSA	KDMS5C	KDM6A	KDR	KEAP1	KEL	KIT	KLHL6
KMT2A (MLL)	KMT2D (MLL2)	KRAS	LTK	LYN	MAF	MAP2K1 (MEK1)	MAP2K2 (MEK2)	MAP2K4
MAP3K1	MAP3K13	MAPK1	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1
MERTK	MET	MITF	MKNK1	MLH1	MPL	MRE11A	MSH2	MSH3
MSH6	MST1R	MTAP	MTOR	MUTYH	MYC	MYCL (MYCL1)	MYCN	MYD88
NBN	NF1	NF2	NFE2L2	NFKB1A	NKX2-1	NOTCH1	NOTCH2	NOTCH3
NPM1	NRAS	NSD3 (WHSC1L1)	NT5C2	NTRK1	NTRK2	NTRK3	P2RY8	PALB2
PARK2	PARP1	PARP2	PARP3	PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)	PDGFRA
PDGFRB	PDK1	PIK3C2B	PIK3C2G	PIK3CA	PIK3CB	PIK3R1	PIM1	PMS2
POLD1	POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI	PTCH1
PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51	RAD51B	RAD51C
RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10	REL	RET
RICTOR	RNF43	ROS1	RPTOR	SDHA	SDHB	SDHC	SDHD	SETD2
SF3B1	SGK1	SMAD2	SMAD4	SMARCA4	SMARCB1	SMO	SNCAIP	SOC3
SOX2	SOX9	SPEN	SPOP	SRC	STAG2	STAT3	STK11	SUFU
SYK	TBX3	TEK	TET2	TGFBR2	TIPARP	TNFAIP3	TNFRSF14	TP53
TSC1	TSC2	TYRO3	U2AF1	VEGFA	VHL	WHSC1	WT1	XPO1
XRCC2	ZNF217	ZNF703						

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	BCL2	BCR	BRAF	BRCA1	BRCA2	CD74	EGFR	ETV4
ETV5	ETV6	EWSR1	EZR	FGFR1	FGFR2	FGFR3	KIT	KMT2A (MLL)
MSH2	MYB	MYC	NOTCH2	NTRK1	NTRK2	NUTM1	PDGFRA	RAF1
RARA	RET	ROS1	RSP02	SDC4	SLC34A2	TERC*	TERT**	TPRSS2

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Loss of Heterozygosity (LOH) score

Microsatellite (MS) status

Tumor Mutational Burden (TMB)

ORDERED TEST # ORD-1156176-01

APPENDIX
About FoundationOne®CDx

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium.


ABOUT FOUNDATIONONE CDx

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details:
www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLES

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture-selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g., gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for ERBB2 and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials
Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. The MSI-H/MSS designation by FMI F1CDx test is based on genome wide analysis of 95 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines. The threshold for MSI-H/MSS was determined by analytical concordance to comparator assays (IHC and PCR) using uterine, cecum and colorectal cancer FFPE tissue. The clinical validity of the qualitative MSI designation has not been established. For Microsatellite Instability (MSI) results, confirmatory testing using a validated orthogonal method should be considered.
2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics

© 2021 Foundation Medicine, Inc. All rights reserved.

ORDERED TEST # ORD-1156176-01

APPENDIX

About FoundationOne®CDx

of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.

3. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
4. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
5. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
6. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive,

and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in <https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/> report the frequency of *HER2* overexpression as 20% in breast cancer. Based on the F1CDx *HER2* CDx concordance study, approximately 10% of *HER2* amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	%CV*
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

*Interquartile Range = 1st Quartile to 3rd Quartile

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *PALB2*, *PMS2*, *POLE*,

RAD51C, *RAD51D*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *TSC2*, and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1*, *CBL*, *DNMT3A*, *IDH2*, *JAK2*, *KMT2D* (*MLL2*), *MPL*, *MYD88*, *SF3B1*, *TET2*, and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating

ORDERED TEST # ORD-1156176-01

APPENDIX

About FoundationOne®CDx

physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
mut/m	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 5.0.0

The median exon coverage for this sample is 966x

ORDERED TEST # ORD-1156176-01

APPENDIX

References

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) PMID: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) PMID: 26140250
3. Lal N, et al. Oncoimmunology (2015) PMID: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) PMID: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Zigelboim I, et al. J. Clin. Oncol. (2007) PMID: 17513808
7. Hampel H, et al. Cancer Res. (2006) PMID: 16885385
8. Stelloo E, et al. Clin. Cancer Res. (2016) PMID: 27006490
9. Kanopienė D, et al. Medicina (Kaunas) (2014) PMID: 25458958
10. Black D, et al. J. Clin. Oncol. (2006) PMID: 16549821
11. Nout RA, et al. Gynecol. Oncol. (2012) PMID: 22609107
12. Steinbakk A, et al. Cell Oncol (Dordr) (2011) PMID: 21547578
13. Bilbao C, et al. Int. J. Radiat. Oncol. Biol. Phys. (2010) PMID: 20005452
14. Guastadisegni C, et al. Eur. J. Cancer (2010) PMID: 20627535
15. Pawlik TM, et al. Dis. Markers (2004) PMID: 15528785
16. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) PMID: 26337942
17. Nature (2012) PMID: 22810696
18. Hiyama T, et al. J. Gastroenterol. Hepatol. (2004) PMID: 15209621
19. Wu MS, et al. Cancer Res. (1998) PMID: 9537253
20. dos Santos NR, et al. Gastroenterology (1996) PMID: 8536886
21. Fang WL, et al. Biomed Res Int (2013) PMID: 23555086
22. Farris AB, et al. Am. J. Surg. Pathol. (2011) PMID: 21422910
23. Agaram NP, et al. Am. J. Clin. Pathol. (2010) PMID: 20395525
24. Ruemmele P, et al. Am. J. Surg. Pathol. (2009) PMID: 19252434
25. Planck M, et al. Cancer (2003) PMID: 12627520
26. Hibi K, et al. Jpn. J. Cancer Res. (1995) PMID: 7775257
27. Muneyuki T, et al. Dig. Dis. Sci. (2000) PMID: 11117578
28. Zhang SH, et al. World J. Gastroenterol. (2005) PMID: 15918185
29. Chiappini F, et al. Carcinogenesis (2004) PMID: 14656944
30. Suto T, et al. J Surg Oncol (2001) PMID: 11223838
31. Momoi H, et al. J. Hepatol. (2001) PMID: 11580146
32. Liengswangwong U, et al. Int. J. Cancer (2003) PMID: 14506736
33. Moy AP, et al. Virchows Arch. (2015) PMID: 25680569
34. Yoshida T, et al. J. Gastroenterol. (2000) PMID: 11063221
35. Pritchard CC, et al. Nat Commun (2014) PMID: 25255306
36. Azzouzi AR, et al. BJU Int. (2007) PMID: 17233803
37. Burger M, et al. J. Mol. Med. (2006) PMID: 16924473
38. Bai S, et al. Am. J. Clin. Pathol. (2013) PMID: 23690119
39. Giedl J, et al. Am. J. Clin. Pathol. (2014) PMID: 25319978
40. Yamamoto Y, et al. Clin. Cancer Res. (2006) PMID: 16675567
41. Smyth et al., 2015; ASCO Gastrointestinal Cancers Symposium Abstract 62
42. Bilbao-Sieyro C, et al. Oncotarget (2014) PMID: 25026289
43. Mackay HJ, et al. Eur. J. Cancer (2010) PMID: 20304627
44. Arabi H, et al. Gynecol. Oncol. (2009) PMID: 19275958
45. You JF, et al. Br. J. Cancer (2010) PMID: 21081928
46. Bairwa NK, et al. Methods Mol. Biol. (2014) PMID: 24623249
47. Boland CR, et al. Cancer Res. (1998) PMID: 9823339
48. Boland CR, et al. Gastroenterology (2010) PMID: 20420947
49. Samstein RM, et al. Nat. Genet. (2019) PMID: 30643254
50. Goodman AM, et al. Mol. Cancer Ther. (2017) PMID: 28835386
51. Goodman AM, et al. Cancer Immunol Res (2019) PMID: 31405947
52. Cristescu R, et al. Science (2018) PMID: 30309915
53. Ready N, et al. J. Clin. Oncol. (2019) PMID: 30785829
54. Hellmann MD, et al. N. Engl. J. Med. (2018) PMID: 29658845
55. Hellmann MD, et al. Cancer Cell (2018) PMID: 29657128
56. Hellmann MD, et al. Cancer Cell (2018) PMID: 29731394
57. Rozeman EA, et al. Nat Med (2021) PMID: 33558721
58. Sharma P, et al. Cancer Cell (2020) PMID: 32916128
59. Marabelle A, et al. Lancet Oncol. (2020) PMID: 32919526
60. Legrand et al., 2018; ASCO Abstract 12000
61. Stadler ZK, et al. J. Clin. Oncol. (2016) PMID: 27022117
62. Cancer Genome Atlas Research Network, et al. Nature (2013) PMID: 23636398
63. Frampton et al., 2016; ASCO Abstract 11558
64. Spigel et al., 2016; ASCO Abstract 9017
65. Jiang et al., 2016; ASCO Abstract e23128
66. Xiao D, et al. Oncotarget (2016) PMID: 27009843
67. Shim HS, et al. J Thorac Oncol (2015) PMID: 26200269
68. Govindan R, et al. Cell (2012) PMID: 22980976
69. Ding L, et al. Nature (2008) PMID: 18948947
70. Imielinski M, et al. Cell (2012) PMID: 22980975
71. Kim Y, et al. J. Clin. Oncol. (2014) PMID: 24323028
72. Samowitz WS, et al. Cancer Epidemiol. Biomarkers Prev. (2001) PMID: 11535541
73. Elsaleh H, et al. Clin Colorectal Cancer (2001) PMID: 12445368
74. Brueckl WM, et al. Anticancer Res. () PMID: 12820457
75. Guidoboni M, et al. Am. J. Pathol. (2001) PMID: 11438476
76. Gryfe R, et al. N. Engl. J. Med. (2000) PMID: 10631274
77. Sinicrope FA, et al. Gastroenterology (2006) PMID: 16952542
78. Laghi L, et al. Dig Dis (2012) PMID: 22722556
79. Mehnert JM, et al. J. Clin. Invest. (2016) PMID: 27159395
80. Hussein YR, et al. Mod. Pathol. (2015) PMID: 25394778
81. Church DN, et al. Hum. Mol. Genet. (2013) PMID: 23528559
82. Cazier JB, et al. Nat Commun (2014) PMID: 24777035
83. Pfeifer GP, et al. Mutat. Res. (2005) PMID: 15748635
84. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) PMID: 23875803
85. Pfeifer GP, et al. Oncogene (2002) PMID: 12379884
86. Rizvi NA, et al. Science (2015) PMID: 25765070
87. Johnson BE, et al. Science (2014) PMID: 24336570
88. Choi S, et al. Neuro-oncology (2018) PMID: 29452419
89. Briggs S, et al. J. Pathol. (2013) PMID: 23447401
90. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) PMID: 24583393
91. Roberts SA, et al. Nat. Rev. Cancer (2014) PMID: 25568919
92. Braun DA, et al. JAMA Oncol (2019) PMID: 31486842
93. Braun DA, et al. Nat Med (2020) PMID: 32472114
94. Miao D, et al. Science (2018) PMID: 29301960
95. Abou Alaiwi S, et al. Cancer Immunol Res (2020) PMID: 32321774
96. Hakimi AA, et al. Nat Commun (2020) PMID: 32820162
97. Miao D, et al. Nat. Genet. (2018) PMID: 30150660
98. Yang Q, et al. Ann Transl Med (2021) PMID: 33850862
99. Varela I, et al. Nature (2011) PMID: 21248752
100. Fujimoto A, et al. Nat Commun (2015) PMID: 25636086
101. Jiao Y, et al. Nat. Genet. (2013) PMID: 24185509
102. Churi CR, et al. PLoS ONE (2014) PMID: 25536104
103. Simbolo M, et al. Oncotarget (2014) PMID: 24867389
104. Nature (2014) PMID: 24476821
105. Robertson AG, et al. Cell (2017) PMID: 28988769
106. Pietzak EJ, et al. Eur. Urol. (2017) PMID: 28583311
107. Williams EA, et al. Acta Neuropathol. (2020) PMID: 32405805
108. Petrini I, et al. Nat. Genet. (2014) PMID: 24974848
109. Tate JG, et al. Nucleic Acids Res. (2019) PMID: 30371878
110. da Costa WH, et al. BJU Int. (2014) PMID: 24053427
111. Pawłowski R, et al. Int. J. Cancer (2013) PMID: 22949125
112. Hakimi AA, et al. Eur. Urol. (2013) PMID: 23036577
113. Numata M, et al. Int. J. Oncol. (2013) PMID: 23229642
114. Hakimi AA, et al. Clin. Cancer Res. (2013) PMID: 23620406
115. Peña-Llopis S, et al. Nat. Genet. (2012) PMID: 22683710
116. Kapur P, et al. Lancet Oncol. (2013) PMID: 23333114
117. Lemon B, et al. Nature () PMID: 11780067
118. Xia W, et al. Cancer Res. (2008) PMID: 18339845
119. Hopson S, et al. ACS Chem. Biol. (2017) PMID: 28921948
120. Porter EG, et al. J. Biol. Chem. (2017) PMID: 28053089
121. Niimi A, et al. Mutat. Res. (2015) PMID: 26117423
122. Brownlee PM, et al. Cell Rep (2014) PMID: 24613357
123. Kakarougkas A, et al. Mol. Cell (2014) PMID: 25066234
124. Gao W, et al. Proc. Natl. Acad. Sci. U.S.A. (2017) PMID: 28082722
125. Chen Z, et al. Biochem Biophys Res Commun (2018) PMID: 29522714
126. Chen BY, et al. Blood (2020) PMID: 32202636
127. Sun XJ, et al. J. Biol. Chem. (2005) PMID: 16118227
128. Faber PW, et al. Hum. Mol. Genet. (1998) PMID: 9700202
129. Al Sarakbi W, et al. BMC Cancer (2009) PMID: 19698110
130. Parker H, et al. Leukemia (2016) PMID: 27282254
131. Zhang J, et al. Nature (2012) PMID: 22237106
132. McKinney M, et al. Cancer Discov (2017) PMID: 28122867
133. Moffitt AB, et al. J. Exp. Med. (2017) PMID: 28424246
134. Zhu X, et al. Nat. Genet. (2014) PMID: 24509477
135. Lu C, et al. Science (2016) PMID: 27174990
136. Jimenez C, et al. J. Clin. Endocrinol. Metab. (2009) PMID: 19017755
137. Kim HC, et al. Cancer Res Treat (2013) PMID: 24454008
138. J Cancer Res Ther () PMID: 26881543
139. Babinska A, et al. Neuro Endocrinol. Lett. (2015) PMID: 26812297
140. Kobayashi A, et al. Intern. Med. (2016) PMID: 26984080
141. Jonasch E, et al. Ann. Oncol. (2011) PMID: 22105611
142. Roma A, et al. Fam. Cancer (2015) PMID: 25391617
143. Rini BI, et al. BJU Int. (2006) PMID: 16827904
144. Choueiri TK, et al. J. Urol. (2008) PMID: 18635227
145. Motzer RJ, et al. Cancer Chemother. Pharmacol. (2014) PMID: 25100134
146. Cho D, et al. Clin Genitourin Cancer (2007) PMID: 17956710
147. Choueiri TK, et al. Clin. Cancer Res. (2013) PMID: 23881929
148. Srinivasan et al., 2021; ASCO Abstract 4555
149. Cowey CL, et al. Curr Oncol Rep (2009) PMID: 19216840

© 2021 Foundation Medicine, Inc. All rights reserved.

Electronically signed by Mirna Lechpammer, M.D., Ph.D. | 12 September 2021
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Shakti Ramkissoon, M.D., Ph.D., M.M. Sc, Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

ORDERED TEST # ORD-1156176-01

APPENDIX **References**

150. Rajaganeshan R, et al. Eur J Surg Oncol (2009) pmid: 19540709
151. Dmitriev AA, et al. Epigenetics (2012) pmid: 22491060
152. Zhao Y, et al. Int. J. Clin. Oncol. (2011) pmid: 21556796
153. Li L, et al. Hematol. Oncol. Clin. North Am. (2011) pmid: 21763962
154. Kaelin WG, et al. Mol. Cell (2008) pmid: 18498744
155. Gnarr JR, et al. Proc. Natl. Acad. Sci. U.S.A. (1996) pmid: 8855222
156. Albers J, et al. EMBO Mol Med (2013) pmid: 23606570
157. Asakawa T, et al. BMC Med. Genet. (2012) pmid: 22462637
158. Banks RE, et al. Cancer Res. (2006) pmid: 16488999
159. Bond J, et al. Blood (2011) pmid: 21454469
160. Clifford SC, et al. Hum. Mol. Genet. (2001) pmid: 11331613
161. Cockman ME, et al. J. Biol. Chem. (2000) pmid: 10823831
162. Corn PG, et al. Nat. Genet. (2003) pmid: 14556007
163. Dandanell M, et al. BMC Med. Genet. (2012) pmid: 22799452
164. Feldman DE, et al. Mol. Cell (1999) pmid: 10635329
165. Feldman DE, et al. Mol. Cell (2003) pmid: 14636579
166. Hansen WJ, et al. Mol. Cell. Biol. (2002) pmid: 11865071
167. Hoffman MA, et al. Hum. Mol. Genet. (2001) pmid: 11331612
168. Khacho M, et al. Mol. Cell. Biol. (2008) pmid: 17967880
169. Kibel A, et al. Science (1995) pmid: 7660130
170. Knauth K, et al. Oncogene (2006) pmid: 16261165
171. Lewis MD, et al. Oncogene (2004) pmid: 14691445
172. Li Z, et al. J. Biol. Chem. (2002) pmid: 11739384
173. Li Z, et al. Biochem. Biophys. Res. Commun. (2002) pmid: 12056827
174. Liu J, et al. PLoS Comput. Biol. (2009) pmid: 19798438
175. Losonczy G, et al. BMC Med. Genet. (2013) pmid: 23298237
176. Maher ER, et al. J. Med. Genet. (1996) pmid: 8730290
177. McClellan AJ, et al. Cell (2005) pmid: 15935760
178. Metzger MB, et al. Mol. Biol. Cell (2009) pmid: 19073890
179. Miller F, et al. J. Biol. Chem. (2005) pmid: 15611064
180. Moore LE, et al. PLoS Genet. (2011) pmid: 22022277
181. Neumann HP, et al. JAMA (1995) pmid: 7563486
182. Ohh M, et al. J. Clin. Invest. (1999) pmid: 10587522
183. Ohh M, et al. Nat. Cell Biol. (2000) pmid: 10878807
184. Olschwang S, et al. Hum. Mutat. (1998) pmid: 9829912
185. Patocs A, et al. BMC Med. Genet. (2008) pmid: 18416845
186. Rechsteiner MP, et al. Cancer Res. (2011) pmid: 21715564
187. Expert Rev Mol Med (2001) pmid: 14987375
188. Ritter MM, et al. J. Clin. Endocrinol. Metab. (1996) pmid: 8772572
189. Schoenfeld AR, et al. Proc. Natl. Acad. Sci. U.S.A. (2000) pmid: 10900011
190. Shmueli MD, et al. PLoS ONE (2013) pmid: 23840444
191. Siu WK, et al. Chin. Med. J. (2011) pmid: 21362373
192. Weirich G, et al. J. Clin. Endocrinol. Metab. (2002) pmid: 12414898
193. Zbar B, et al. Hum. Mutat. (1996) pmid: 8956040
194. Zhou MI, et al. Cancer Res. (2004) pmid: 14973063
195. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
196. Maher ER, et al. Eur. J. Hum. Genet. (2011) pmid: 21386872
197. Haddad NM, et al. Semin Ophthalmol () pmid: 24138046
198. Richard S, et al. Semin. Cancer Biol. (2013) pmid: 22659535